ASCO 2020 | ALTERNATE: fulvestrant and/or anastrozole in ER+ HER2- postmenopausal breast cancer

Cynthia X. Ma, MD, PhD, Washington University School of Medicine, St. Louis, MI, outlines the ALTERNATE trial (NCT01953588), investigating neoadjuvant endocrine therapy with fulvestrant or the combination of anastrozole and fulvestrant for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer in postmenopausal women. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).